Bayer, Sherbrooke to advance mastitis vaccine

Strategic licensing transaction focuses on advancing novel vaccine candidate for mastitis affecting dairy herds.

Bayer and TransferTech Sherbrooke, the corporate entity responsible for commercializing innovations emerging from the Universite de Sherbrooke in Quebec and its affiliated institutions, have signed a global license agreement to advance a novel vaccine candidate discovered at Universite de Sherbrooke to help protect dairy cattle from mastitis caused by the bacterium Staphylococcus aureus.

Mastitis is a complex infectious disease. It is the most common and costly production

All access premium subscription

This content requires a subscription to Feedstuffs in order to access. If you are a paid subscriber, use your email and password to Log In now.

Current Feedstuffs Subscribers: Online and mobile access are now included at no charge to you. To read this article, use your subscriber email and password to log-in to your account (or contact us for assistance in updating your account.)

Not Currently a Subscriber: Subscribe NOW to Feedstuffs and receive our print and/or digital publications, enewsletters and premium online content. Visit and click on Subscribe at the top of the page for more information.



Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.